Table 1 Patient and sample characteristics and sequencing results obtained by the laboratories involved in the study

From: Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks

Patient Sex Age (years) Date of sampling CERFIG PFHG IPD
Ct valuea Genome recovery (%) Ct valuea Genome recovery (%) Ct valuea Genome recovery (%)
1 F 54 12 February 2021b 22.4 87.8 29.3 99.6
    19 February 2021c 33.1 0.3
2 F 70 12 February 2021b 25.9 67.8 37.1 98.7
3 M 61 13 February 2021b 29.4 5.0 Neg. 7.5 Neg. 2.5
4 M 46 20 February 2021c 24.3 12.6
5 M 22 22 February 2021b 32.5 99.4 23.2 93.3
6 M 65 23 February 2021c 20.5 97.3
7 F 75 26 February 2021b 19.5 95.5
8 M 29 26 February 2021b 18.8 98.1
9 M 32 26 February 2021b 24.6 99.9 27.8 77.6
10 F 30 26 February 2021b 26.0 99.7 23.0 82.2
11 F 55 26 February 2021b 36.4 75.4 28.8 82.9
12 M 45 26 February 2021b 20.5 96.1
13 M 42 26 February 2021b 25.0 99.9 29.3 70.4
14 F 40 4 March 2021b 22.0 97.5
  1. aCycle threshold (Ct) value was measured in the sequencing laboratory before starting the sequencing process.
  2. bPatient samples obtained at diagnosis.
  3. cFollow-up samples from patients.
  4. All samples from patients were whole EDTA blood, except for patient 12 for whom a swab was used.
  5. – indicates that the sample was not tested in this laboratory. The values differ between laboratories owing to possible degradation of the sample or the RNA during transport and storage.
  6. Neg., negative.